Effect of polyphenol-containing hepatoprotectors on the experimental chronic hepatitis pattern


Chronic hepatitis and cirrhosis cases are treated with hepatoprotective drugs preventing patients from developing metabolic, functional, and structural disorder in hepatocytes [ 1]. However, the ability of hepatoprotectors to reduce the leading manifestation of chronic liver pathology, namely, the proliferation of connective tissue, has been argued [2]. The discovery of antiproliferative properties in hepatoprotectors is very important from the standpoint of clinical strategy. Indeed, such preparations would allow us in some cases to reject the use of highly toxic glucocorticoids that are currently considered the only effective drugs suppressing the proliferation of fibrous tissue in liver [3]. In this paper, we present data on the therapeutic efficiency of polyphenol-containing hepatoprotectors, maxar and legalon, summarized upon treating chronic hepatitis induced in rats by prolonged introduction of CCI4. Maxar is an original preparation representing a combination of polyphenols extracted from core wood pulp of a Far Eastern plant (Maackia amurensis Rupr. et Maxim.), including isoflavones (formonetin, genistein, retusin, 4,7-dihydro-Y-methoxyisoflavone), stilbenes (rasveratol, 3,3',4,5-tetrahydrostilbene), and isoflavonostilbene maackiasine [4]. Legalon contains a combination of polyoxyphenylchromanones (silybine, silydianine, silychristine) extracted from seeds of a plant (Silybum" marianum Gaertn.) [5, 6]. Both phytopreparations exhibit pronounced hepatoprotective and antioxidant activity with respect to experimental acute hepatitis induced by intoxication with CC t4, para-cetaol, altyl alcohol, and D-galactosamine [1, 5, 7]. Experiments were performed on 70 white male rats weighing 180200 g. Two groups of test animals were

DOI: 10.1007/BF02218867

1 Figure or Table

Cite this paper

@article{Vengerovskii2005EffectOP, title={Effect of polyphenol-containing hepatoprotectors on the experimental chronic hepatitis pattern}, author={A. I. Vengerovskii and Nik{\vs}a Baturina and V. S. Chuchalin and A. S. Saratikov}, journal={Pharmaceutical Chemistry Journal}, year={2005}, volume={30}, pages={69-71} }